Twelve large cell carcinomas of the lung showing evidence of neuroendocrine differentiation (LCCND) were compared with 15 other large cell pulmonary tumors that lacked such features (NELCUC). All lesions were composed of partially necrotic, nested, or sheet-like arrays of mitotically active, nucleolated large cells that were at least twice the size of those seen in small cell carcinomas. Examples of LCCND were defined by immunoreactivity for neuron-specific enolase, Leu-7, synaptophysin, and chromogranin-A, and by their content of neurosecretory granules on electron microscopy. NELCUCs were devoid of these immunohistologic and ultrastructural features. There were six women and six men with LCCND, who ranged in age from 38 to 82 years. Of nine individuals in this group with Stage
T1NOMO or T2NOMO disease at diagnosis, five (55%) died of their neoplasms within 3 years of diagnosis; three more (33%) have recurrent or persistent tumors and are likely to die as a result. On the other hand, 47% of patients with NELCUC of similar stages are free of disease after a similar follow-up period. LCCND is a distinctive clinicopathologic disease and should not be classified with unspecified large cell anaplastic carcinomas of the lung. Its behavior is potentially aggressive and may justify consideration of a specialized treatment protocol. Because electron microscopic evaluation of immunohistologic features must be done to recognize LCCND, it is probably underdiagnosed. (Key words: Lung neoplasms; Neuroendocrine tumors; Largecell carcinomas; Electron microscopy) Am J Clin Pathol 1992; 97:796-805 apy. 5 Nevertheless, large cell undifferentiated carcinomas of the lung (LCUC) are more heterogeneous, with respect to their biologic evolution and their morphologic attributes. 6 Ultrastructural and immunohistochemical studies have delineated occult squamous, glandular, and neuroendocrine features in such neoplasms. 6, 7 The last of these findings-that of neuroendocrine differentiation in large cell anaplastic carcinomas-has been reported relatively infrequently in the pathology literature. 6 " 10 In an effort to better define the clinicopathologic characteristics of tumors with such features, we compared 12 such lesions with 15 of nonendocrine LCUC in a detailed fashion. The results of that analysis constitute the basis of the following report.
MATERIALS AND METHODS
Ten cases included in this report were taken from the consultation files of one of the authors (MRW). Seventeen additional tumors were retrieved from the surgical pathology files at Barnes Hospital, Washington University Medical Center, St. Louis, Missouri.
On average, seven microscopic sections of each neo-WICK, BERG, AND HERTZ 797 Large Cell Carcinoma of the Lung with Neuroendocrine Differentiation plasm were reviewed. Criteria used for a diagnosis of large cell undifferentiated carcinoma with neuroendocrine differentiation (LCCND) were based on a combination of histologic, immunohistochemical, and ultrastructural features. These included a cell size approximating that of poorly differentiated adenocarcinoma, squamous cell carcinoma, or "large cell undifferentiated" carcinoma, and at least twice that of small cell carcinoma; the lack of overt squamous or glandular differentiation despite thorough sampling; and a nuclear appearance featuring monomorphism and dispersed or vesicular chromatin with discernible nucleoli. These microscopic features are identical to those proposed for a diagnosis of large cell undifferentiated carcinoma by the World Health Organization." In addition, immunohistochemical or electron microscopic evidence of neuroendocrine differentiation (see below) was required to assign the diagnostic label of LCCND. Cases were only categorized as nonendocrine LCUC (NELCUC) if no ultrastructural or immunologic neuroendocrine features could be identified; among 25 nonconsultation cases of LCUC that were screened for these attributes, 2 showed immunohistologic evidence of a neuroendocrine lineage and were reassigned to the LCCND group. A selected group of 15 of the remaining LCUC cases were retained for further analysis, based on their limited clinical stage at diagnosis, to facilitate a biologic comparison of LCCND and NELCUC.
Complete clinical information on each patient was obtained by review of medical records, and correspondence with primary physicians and oncologists. Several hematoxylin-and-eosin-stained slides were available for review in all instances, with an average of three per case. Formalin-fixed, paraffin-embedded tissue from all neoplasms was used for immunohistochemical analysis, as detailed below. In 10 cases, fresh tissue also had been fixed in 3% phosphate-buffered glutaraldehyde and postfixed in osmium tetroxide, embedded in epoxy resin, mounted on copper grids, and stained with lead citrate and uranyl acetate, before examination with a Philips 201 electron microscope (Philips, Eindhoven, The Netherlands).
For immunohistochemical studies, paraffin sections were cut at 5 fim and mounted on glass slides coated with a chrome-alum mixture. After deparaffinization in Americlear (American Scientific Products, McGaw Park, IL) and absolute ethanol, they were incubated for 30 minutes in 6% methanolic hydrogen peroxide to block endogenous peroxidase activity. Rehydration was accomplished with graded ethanol solutions, distilled water, and phosphatebuffered saline (pH 7.4).
Sections to be labeled with anti-cytokeratins were predigested with 0.4% ficin (Sigma Biochemical Co., St. Louis, MO; catalog F4125) for 20 minutes at room temperature. This step was not employed in other immunostains because previous evaluations in our laboratory showed it to be detrimental to final results. 12 Afterward all slides were incubated with primary antibodies to cytokeratin, neuron-specific (gamma dimer) enolase (NSE), Leu 7, chromogranin-A, and synaptophysin. In addition, five cases were studied for their content of calcitonin, serotonin, adrenocorticotrophic hormone, and somatostatin ( Table 1 ). The antiserum to NSE used in our laboratory was absorbed extensively with dried, acetone-fixed human tissues containing nongamma enolase monomers to obtain a monospecific reagent.
Subsequent immunohistochemical development used the avidin-biotin-peroxidase complex method, as described previously. 13 Chromogenic development was obtained by immersion of the sections in 3,3'-diaminobenzidine hydrochloride solution (Sigma Biochemical Co., St. Louis, MO; 0.25 mg/mL with 0.003% hydrogen peroxide) for a maximum of 10 minutes. They were counterstained with Harris' hematoxylin and examined by light microscopy.
Positive controls consisted of stock tumors known to 
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Original Article contain the determinants of interest. All study cases also were labeled with avidin-biotin-peroxidase complex after substitution of nonimmune rabbit serum and mouse ascites fluid for primary antibodies; these served as negative controls.
RESULTS

Clinical Data (Table 2)
Six patients with LCCND were men and six were women, ranging in age from 38 to 82 years at diagnosis (mean, 67 years). The most common presenting complaints included cough, weight loss, and general malaise; two neoplasms were found incidentally on chest roentgenograms taken during routine health assessment examinations, and another patient presented with tonicclonic seizures. The latter individual had cerebral metastases at diagnosis. None of the 12 patients with LCCND demonstrated clinical or laboratory evidence of Cushing's syndrome, hyponatremia, osteoarthropathy, or other paraneoplastic phenomena. All patients whose personal habits had been recorded were cigarette smokers (nine cases). Ten men and five women with NELCUC were evaluated; their ages ranged from 49 to 76 years (mean, 67 years) and they were all smokers. Most presenting symptoms were cough, hemoptysis, or recurrent pneumonia (10 cases). In five cases, the lesions were discovered on screening chest roentgenograms.
Radiographic evaluation revealed that all examples of LCCND were located in the peripheral lung fields and varied in size from 3 to 8 cm in greatest dimension. They were moderately radioopaque and were rounded or slightly irregular in contour; stippled internal calcification was seen within the neoplasms in two examples. There was no predilection for the right or the left lung. NELCUC was observed in both the peripheral aspects of the lungs (9 cases) and the perihilar region (6 cases) as dense, irregular, 4-to 9.5-cm masses without internal calcification. Eight of these tumors were located in the right lung, and seven were found on the left lung.
All patients underwent exploratory mediastinoscopy, followed by thoracotomy. Lobectomies were undertaken T1N0M0  T2N0M0  T1N0M0  T2N0M0  T2N0M0  T1N0M0  T1N0M0  T2N0M0  T2N0M0  T2N0M0  T1N0M0  T2N0M0  T2N0M0  T1N0M0 Large Cell Carcinoma of the Lung in nine cases of LCCND, whereas the other patients with this tumor type were managed primarily with irradiation (one case), chemotherapy (one case), or both (one case), after a diagnosis had been established by excisional biopsy. One patient with LCCND was treated with surgery alone, whereas the remaining surgically treated individuals received adjuvant radiotherapy to the mediastinum or chemotherapy. In cases in which irradiation was used, an average of 7,500 Rad was administered to the lesional area and pulmonary hilum in fractionated doses. Cyclic chemotherapeutic regimens used for LCCND included cisplatin + etoposide, and cyclophosphamide + doxorubicin + vincristine, with or without cisplatin. In contrast, all patients with NELCUC underwent lobectomy after mediastinoscopy had been performed. Five received adjuvant radiotherapy to the thorax for regional tumor recurrences, and seven were given chemotherapy with one of two regimens (vindesine + cisplatin, or cyclophosphamide + doxorubicin + methotrexate + procarbazine) for subsequent metastatic disease.
Nine patients with LCCND had clinical Stages T1NOMO or T2NOMO disease (American Joint Committee for Cancer staging system, Mountain Revision 14 ) at presentation. Two individuals in this group had metastatic involvement of hilar lymph nodes at diagnosis (Stage T2N1MO); only one demonstrated nodal spread as well as distant extrathoracic metastases, involving the brain (stage T2N1M1). Because of the design of this study, all examples of NELCUC were Stage TINOMO (six cases) or T2NOMO (nine cases).
Conventional Pathologic Findings
Macroscopic examination revealed that resected examples of both LCCND and NELCUC were firm, greywhite, sometimes gritty masses that contained foci of internal necrosis and hemorrhage in some instances. One neoplasm was located subjacent to the pleural surface and caused retractional "puckering" of the serosa. None exhibited zones of perilesional fibrosis within the pulmonary parenchyma.
Histologically, all neoplasms were typified by organoid growth, or medullary and trabecular arrays of polygonal tumor cells with prominent areas of central necrosis. The latter feature yielded a "geographic" growth pattern seen with low-power microscopic examination in most cases. Lesional stroma was composed of delicate fibrous tissue, punctuated by foci of vascular ectasia and hemorrhage. Neoplastic cells were 7 to 10 times the size of erythrocytes and contained oval or round nuclei (Fig. 1 ). Chromatin was dispersed or vesicular with conspicuous nucleoli (Fig.  2) , and cytoplasm was moderate in amount and amphophilic; granularity was inapparent. Three cases exhibited th Neuroendocrine Differentiation focal spindle-cell change. Mitotic activity was brisk, ranging from three to eight division figures per high-power (X400) microscopic field. Overt keratinization, wellformed glands, giant cells, and peripherolobular nuclear palisading were not observed. Four tumors, which later were proved to represent LCCND, exhibited limited formation of rosettes in which tumor cells surrounded small lumen-like spaces.
Ultrastructural Features
Four cases of LCCND that were studied by electron microscopic examination had uniform ultrastructural features. They were composed of polygonal cells connected by macula adherens-type junctional complexes, unassociated with pericellular basal lamina. The intercellular space contained scant numbers of collagen fibrils. Nuclei were located centrally and manifested an admixture of heterochromatin and euchromatin; nucleoli were compact and lacked nucleolonemata.
The cytoplasm contained standard metabolic organelles, with occasionally prominent Golgi bodies. Tonofilaments, microvilli, and glandular microlumina were not evident in the tissue sampled. Both tumors exhibited the presence of small numbers of intracellular dense-core (neurosecretory) granules, which were dispersed randomly throughout the cytoplasm. These structures measured 80 to 120 nm in diameter and were uniform in shape ( Fig.  3 ). Small skeins of intermediate (7 to 10 nm) filaments also were distributed evenly within the tumor cells.
Among six examples of NELCUC that were analyzed using the electron microscope, none contained neurosecretory granules. Two showed short bundles of broad cytoplasmic tonofibrils, but none manifested the presence of luminal differentiation. Other ultrastructural features were virtually identical to those of LCCND, as described above. (Table 3) Each of the 12 cases of LCCND expressed strong immunoreactivity for cytokeratin, with a crisp cytoplasmic staining pattern; none manifested a paranuclear accentuation of positivity for this determinant. Eleven LCCNDs were reactive for NSE, with a diffuse cytoplasmic pattern. Five lesions expressed delicately granular positivity for chromogranin-A ( Fig. 4) , seven were reactive for synaptophysin (Fig. 5) , and four exhibited multifocal Leu 7 reactivity. Cytoplasmic neuropeptides were demonstrable in all five neoplasms in which they were sought immunohistochemically; three LCCNDs were labeled for calcitonin, two expressed somatostatin, and another was immunoreactive for serotonin. None contained ACTH. All 
Immunohistochemical Data
Follow-up Information (Table 2)
Clinical follow-up in cases of LCCND ranged from 27 to 50 months after diagnosis and treatment. Four patients were alive at last contact, with two being free of disease and two having developed hilar, cerebral, or supraclavicular lymph node metastases of their neoplasms. Two patients with metastatic disease at initial evaluation died shortly after the initiation of radiation therapy (at 4 and 19 days).
Both individuals who were free of metastases received chemotherapy after a lobectomy was performed. All except two tumors for which radiotherapy was administered proved fatal. On the other hand, all four patients who were still alive at last follow-up had received chemotherapy.
Seven patients with NELCUC were alive and free of disease at last follow-up (range, 32 to 66 months) and three were alive with local intrathoracic recurrence. Five Vol. 97 th Neuroendocrine Differentiation individuals with this tumor type had local recurrence or distant metastasis within 36 months of diagnosis and died of their tumors. Adjuvant irradiation and chemotherapy was reserved largely for those patients with postoperative relapse of NELCUC and was administered in only one other case.
DISCUSSION
Most pathologists are aware that "large cell undifferentiated" pulmonary carcinomas constitute a mixture of ultrastructural types. 61516 Although they may appear to be identical by conventional microscopic examination, electron microscopic analysis often demonstrates previously occult evidence of squamous or glandular differentiation. 1516 Nevertheless, it is only in the last decade that reports of neuroendocrine characteristics have appeared in this category of lung cancer. 610 In the context of current concepts on neoplasia, these observations are not unexpected; it is now known that poorly differentiated carcinomas in a variety of sites-including the gut, urinary bladder, skin, and genital tract, among others-may exhibit a mixture of squamous, glandular, and neuroendocrine features. 17 " 20 Indeed, predominant neuroendocrine differentiation is being increasingly recognized in primitive tumors of the lung that are not easily placed into the diagnostic categories of "carcinoid" or "oat cell carcinoma," with the latter designations representing opposite poles of a cellular spectrum. 9 This report concerns 12 examples of such neoplasms. We have chosen to label them "large cell undifferentiated carcinomas with neuroendocrine differentiation," instead of "atypical endocrine tumors." 21 Some . 4 (upper) . Immunoreactivity for chromogranin-A (CGA), in large cell anaplastic carcinoma with neuroendocrine differentiation (Anti-CGA/ABC immunostain, X200).
TABLE 3 . IMMUNOREACTrVITY P A T T E R N S A N D RESULTS
OF ELECTRON MICROSCOPY IN LARGE CELL C A R C I N O M A S OF THE L U N G WITH EVIDENCE OF N E U R O E N D O C R I N E DIFFERENTIATION
FlG. 5 (lower). Diffuse immunohistochemical reactivity for synaptophysin (SYN), in large cell carcinoma of the lung with neuroendocrine differentiation (anti-SYN/ ABC immunostain, X200).
observers also may think that the characteristics of the lesions we have reported are partially shared by "atypical carcinoids," as described by Arrigoni and Bernatz, 22 and other authors. 2324 However, there were important differ-ences between the latter neoplasms and LCCND, such as those relating to cellular size, nuclear features, and overall growth pattern. Furthermore, we favor abandoning the diagnosis of "atypical carcinoid" altogether.
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The reasons underlying the latter opinion are twofold. The first relates to the fact that "atypical carcinoid" is defined differently by various pathologists, resulting in nonuniform acceptance of this lesion as a tumor entity. 25 The second is based on our experience with clinicians' responses to this pathologic interpretation. In particular, some oncologists are loath to administer adjuvant therapy to tumors labeled as pulmonary "carcinoid," atypical or otherwise. This reluctance stems from their familiarity with the behavior of central classical carcinoids of the lung, which follow a relatively innocuous course and usually fail to metastasize. 26 ' 27 On the other hand, patients with LCCND that are interpreted as LCUC, not otherwise specified, are commonly treated with irradiation or chemotherapy protocols designed for non-small cell carcinomas. 10 This is a decision that, as discussed subsequently, we also believe may be unwise. The points just made are not novel; they have been outlined previously by Hammond and Sause, 10 Neal and colleagues, 28 McDowell and associates, 21 and by Piehl and co-workers, 6 and emphasized by Warren and others. 29 Nonetheless, the conclusions of these authors continue to go unheeded and therefore merit repetition and reemphasis.
It also should be stated that our cases did not have the histologic appearance of "large cell neuroendocrine carcinoma," as described by Travis and associates. 30 The latter authors reserved such a designation for large cell lesions that were clearly neuroendocrine on cytologic and architectural grounds by routine light microscopic examination and that had a high mitotic rate and prominent nucleoli. Other investigators have included such neoplasms under the rubric of "intermediate cell neuroendocrine carcinoma." 29 The tumors described as LCCND in our series could not be identified as endocrine in nature unless special studies were applied, corresponding to lesions that Travis and associates 30 considered to be "non-small cell carcinomas with neuroendocrine features."
Two generally available methods exist to detect neuroendocrine attributes in large cell carcinomas of the lung. The first involves the electron microscopic observation of cytoplasmic neurosecretory granules, 31 which are uniform in shape and range from 80 to 300 nm in diameter. The second, immunohistologic evaluation, represents an effective and less expensive means to this end. Several antigenic markers for neuroendocrine cells may be used, including chromogranin-A; Leu 7; synaptophysin; lungassociated neuropeptides such as bombesin, calcitonin, somatostatin, and adrenocorticotrophic hormone; protein gene product 9.5, and NSE. 32~37 In regard to the last of these determinants, it is preferable to use an absorbed, monospecific antiserum to NSE or monoclonal antibodies to gamma-dimeric enolase because of unwanted crossreactivity that is sometimes seen with native heteroantisera. 38 If this proviso is met, reactivity for any one of the discriminants just cited can be equated with the presence of neuroendocrine differentiation. 37 Admittedly, however, this conclusion is firmest when chromogranin-A, synaptophysin, or Leu 7 are demonstrable in the tumor cells.
The current series recapitulates the observations of other reports, 6 ' 1021 ' 28 ' 29 ' 3940 in that 67% of our patients with LCCND died of their neoplasms and another 17% are likely to do so in the future. Piehl and colleagues 6 and Warren and co-workers 29 documented a mortality rate of 84% in similar cases. Such results, as well as our own, attest to the potential aggressiveness of these tumors, which must be distinguished from classical carcinoid, "well-differentiated" neuroendocrine carcinoma, 29, 30 and NELCUC. A review of the literature (Table 4 ) reveals 52 additional cases of neoplasms that are representative of pulmonary LCCND, for which follow-up data are available. Forty of these patients (77%) died of their tumors within 5 years of diagnosis, having undergone surgical extirpation in most instances, and the administration of varying adjuvant treatment modalities.
By comparison, classical pulmonary carcinoid has a 5year mortality rate of less than 15% 26, 27 ; "atypical carcinoid" (well-differentiated neuroendocrine carcinoma 29 ) is fatal in 30% to 40% of cases 23 ' 24,29 ; non-neuroendocrine large cell undifferentiated carcinoma of the lung is associated with a mortality rate of approximately 50% (see Ishida and associates 41 and the current series); and both large and small cell neuroendocrine carcinomas are fatal in more than 95% of cases. 30 ' 42 These data suggest that the accurate pathologic separation of these lesions has more than academic significance. With respect to detailed recommendations on therapy, the following points seem worthy of consideration.
1. Radiotherapy may be helpful in the local control of LCCND or palliation of metastatic disease, but it probably should not be used in the absence of cytotoxic drug treatment. This premise stems from the fact that two of our patients died of disease after irradiation delayed the administration of chemotherapy. 2. There is probably a role for surgical excision of Stages T1NOMO and T2NOMO LCCND before adjuvant treatment. Several survivors in previous series 6 ' 21 ' 28 ' 39 were managed in this fashion, as was a sizable subset of our patients. 3. Specific cytotoxic agents that are active against LCCND have not been evaluated prospectively in a controlled fashion. Nonetheless, in view of the biologic attributes of this tumor that are shared with pulmonary oat cell carcinoma, it seems reasonable to use pharmaceutical combinations to treat the latter neoplasm, 2 as in several of our cases. Protocol trials will be necessary in the future to provide definitive data on this point and to compare the efficacy of such regimens with those used for non-neuroendocrine large cell carcinomas of the lung.
In summary, large cell anaplastic carcinoma of the lung with neuroendocrine differentiation is virtually identical histologically to NELCUC. In light of apparent differences in behavior between these two lesions, it is suggested that immunohistochemical or ultrastructural analysis should be performed on all poorly differentiated large cell epithelial neoplasms of the lung. Optimal therapeutic approaches for this group of tumors will only be achieved through such measures.
